Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic, suggests that some patients with indolent systemic mastocytosis (ISM) may be progressing at a faster rate than expected, and will need to be monitored and started on appropriate therapies.
Data on disease progression among patients with indolent systemic mastocytosis (ISM) are limited and have clinical implications. Therefore, having a better understanding of survival outcomes among these patients can lead to timely treatment interventions and potentially improved outcomes.
The data found in this population-level analysis suggest that perhaps not all patients with ISM are truly indolent, says Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology at Cleveland Clinic.
Transcript
What motivated the need for this large-scale population level analysis in the US on overall survival in patients with indolent systemic mastocytosis (ISM)?
Systemic mastocytosis or mast cell disease are a very heterogeneous group of diseases. As per the WHO [World Health Organization] classification, indolent systemic mastocytosis is one of the entities under the umbrella of systemic mastocytosis. As the name "indolent" suggests, it gives us a perception that these diseases are indolent, which means they may remain quiet for a long time without causing any kind of difficulties or symptomatic problems to the patients. The reason why we conducted this large population-based study from the US is there has been a spade of studies recently that have shown that compared to the previously held notion that patients with indolent systemic mastocytosis have an indolent course, recent studies suggest that may not be the case.
For example, in 2019, a paper published in Lancet Haematology looked at 1006 indolent systemic mastocytosis patients. This was from the European Cutaneous Mastocytosis Network registry that showed when these 1000 patients with ISM were compared to patients with cutaneous mastocytosis, their survival was diminished. More recently, a population-level study from the Danish National Health Registry included close to about 400 ISM patients, and this was compared to a non-ISM–matched cohort, which showed that the mortality was increased in patients with ISM, with a hazard ratio that fluctuated between 1.53 and 2.59, with a median follow-up of 9 years.
These data are provocative and troubling, and it does challenge our perception and notion that maybe not all ISM patients need to be considered indolent. There might be some among these who are progressing at a faster rate and therefore need to be clinically monitored and started on appropriate therapies.
This led us to look at the outcome or the survival of the ISM patients, particularly in the US, because there have not been any significant, large scale population-level studies on systemic mastocytosis from the US. Most of the data that we have come from the European registries.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More